



Biotech Daily

Tuesday September 8, 2026

Daily news on ASX-listed biotechnology companies

- * **ASX DOWN, BIOTECH EVEN: LUMOS UP 15%; COMPUMEDICS DOWN 6%**
- * **QIMR INVESTIGATES GUT FOR DEPRESSION**
- * **ONCOSIL RAISES \$5.6m; 100th TREATED PATIENT IN SPAIN**
- * **BTC: ARIDOL, BRONCHITOL MAKER ARNA IN ADMINISTRATION**
- * **EMYRIA READIES SYDNEY PSYCHEDELICS CLINIC FOR MENTAL HEALTH**
- * **CLINUVEL DEVELOPS ZEROKIN FOR SUB-CUTANEOUS DRUG DELIVERY**
- * **ANTEOTECH BATTERY SUPPLY FOR AIRSPEEDER FLYING CARS**
- * **DR RAPHAEL BERNIER REPLACES BLINKLAB'S DR RICHARD HOPKINS**
- * **NEUROTECH: CHAPMAN, IN; DR FILIPPIS OUT; JOHNSTON TO GO**

MARKET REPORT

The Australian stock market fell one percent on Tuesday September 8, 2026, with the ASX200 down 90.1 points to 8920.8 points.

Fifteen of the Biotech Daily Top 40 companies were up, 14 fell and 11 traded unchanged.

Lumos was the best, up 1.5 cents or 15.0 percent to 11.5 cents, with 2.7 million shares traded.

Resonance climbed 10.7 percent; Actinogen was up 6.8 percent; both EBR and Medical Developments were up 5.3 percent; Clarity climbed 4.4 percent; Nova Eye was up 3.7 percent; Immutep, Mesoblast and Nanosonics rose more than two percent; Polynovo, Saluda, Starpharma and Telix were up more than one percent; with CSL, Neuren, Pro Medicus and Resmed up by less than one percent.

Compumedics led the falls, down 1.5 cents or 6.0 percent to 23.5 cents, with 2,001 shares traded. 4D Medical, Alcidion, Imugene, Micro-X and Prescient fell more than four percent; Aroa, Dimerix and Proteomics were down more than three percent; Artrya and Emvision shed more than two percent; Clinuvel and Imricor were down more than one percent; with Avita and Cochlear down by less than one percent.

QUEENSLAND INSTITUTE OF MEDICAL RESEARCH BERGHOFER

The Queensland Institute of Medical Research says it has identified a genetic link between gut-related health conditions and depression.

The QIMR Berghofer said the study offered “new insights into why physical illnesses often accompany the mental health condition ... [and] physical illnesses can contribute substantially to poor health outcomes in people with depression, who die up to 12 years earlier than those without the condition”.

The research, titled ‘Dissecting pleiotropy between major depressive disorder and physical disease comorbidities’, was published in Nature Genetics and the full article is available at: <https://www.nature.com/articles/s41588-026-02735-3>.

QIMR said it studied the genetic relationship between major depressive disorder and four disease groups: cardiovascular, metabolic, gastrointestinal and immune disorders.

The Institute said that while all four groups of diseases were genetically linked to depression, gastro-intestinal diseases such as irritable bowel syndrome, gastro-oesophageal reflux, gallstones and peptic ulcers showed the strongest association.

QIMR said the genetic risk factors linked to these physical illnesses overlapped with almost half of those involved in depression.

The Institute’s lead author and doctoral student Damian Woodward said the findings “highlight the importance of looking beyond the brain when treating depression”.

“We found gastro-intestinal diseases had the strongest shared genetic relationship with depression, confirming that the gut-brain axis plays a key role in why depression commonly occurs alongside physical illness,” Mr Woodward said.

“The gut is often referred to as the second brain, sharing many of the same signaling chemicals and containing a high number of nerve cells,” Mr Woodward said.

“There is a constant communication between the gut and brain, and we identify genetic roots that affect this communication contributing to depression, gut dysfunction, and even other conditions such as immune-related diseases,” Mr Woodward said.

QIMR said that in addition to raising clinical awareness of conditions shared by people with depression, researchers were hoping to identify new treatment options, including repurposing existing medications.

ONCOSIL MEDICAL

Oncosil says it will raise \$4 million in a placement at \$1.00 a share and \$1.6 million from an options exercise at 90 cents each; and has treated its one hundredth patient in Spain.

Oncosil said its three largest investors, Pengana High Conviction Equities Fund, Regal Partners and Australian Ethical Investments, supported the capital raise; with the placement at a 9.9 percent premium to the last closing price on September 7, 2026.

The company said the funds would support the commercial launch of its device.

Oncosil chair Dr Thomas Duthy said that with US Food and Drug Administration approval for distal cholangio-carcinoma, a bile duct cancer and Australian Therapeutic Goods Administration approval for pancreatic cancer, “this capital will support our transition into commercialization in the US and Australia” (BD: May 20, Aug 17, 2026).

The company said it was targeting several milestones by the end of the year, including the G-BA funded study, two additional European regulatory filings and the start of manufacturing at the Oncosil/Cyclotek facility.

Separately, Oncosil said it had treated the one hundredth pancreatic cancer patient at Hospital HM Sanchinarro, Madrid, on September 7, 2026.

The company said Spain had about 9,200 new cases of pancreatic cancer each year.

Oncosil was up 15.5 cents or 17.0 percent to \$1.065.

BTC HEALTH

BTC says that Aridol and Bronchitol manufacturer Arna Pharma Pty Ltd was placed into voluntary administration on September 7, 2026.

BTC said that subsidiary BTC Pharma Pty Ltd was a customer of Arna Pharma, the Australian sponsor of both Australian Therapeutic Goods Administration-registered products and held the exclusive distribution rights.

The company said Bronchitol, or mannitol dry powder, for cystic fibrosis was listed on the Pharmaceutical Benefits Scheme.

In 2023, the then Pharmaxis, now Syntara, said Arna Pharma bought its mannitol business including Bronchitol and the Aridol asthma test products (BD: Oct 3, 2023).

Today, BTC said that neither it nor BTC Pharma was “a shareholder, lender, guarantor or related party of Arna Pharma, there are no directors in common, and the group has no exposure to the administration other than ordinary supply arrangements”.

BTC said that its subsidiary held about eight months of Bronchitol stock and less than one month of Aridol stock.

The company said that Arna Pharma intended to recapitalize the business and maintain continuity of supply.

BTC said that it could not “verify that position and gives no assurance that manufacture or supply will resume”.

BTC said Aridol and Bronchitol generated sales of \$1.1 million in 2025-'2026 and without further supply of these products, BTC Health expects sales of Aridol and Bronchitol to be up to \$500,000 million in 2026-'27.

The company said that BTC Pharma was “engaging with the administrators and, as sponsor of both products, with the Therapeutic Goods Administration and the Department of Health, Disability and Ageing regarding continuity of supply”.

BTC was untraded at 6.0 cents.

EMYRIA

Emyria says its Sydney clinic fit-out is complete with four treatment rooms, about 20 therapists and four psychiatrists for the planned September 2026 opening.

Emyria said that the Australian Therapeutic Goods Administration had endorsed the first two Sydney authorized prescribers, with medication supply and healthcare partnerships secured, along with a formal agreement with Matilda Nepean Private Hospital and the first patients approved for treatment.

The company said that the Sydney launch expanded the company into Australia's largest population market, its first New South Wales presence “and broadening access to evidence-based mental health treatments amid growing demand”.

In 2024, Emyria said it opened a Perth Empax Centre evaluating 3,4 methylene-dioxy-meth-amphetamine (MDMA) therapy and later said it had Perth, Brisbane and Mornington, Victoria centres (BD: Apr 10, 2024; Apr 14, Jul 29, 2025; Mar 24, 2026).

In April, the company said it would open a clinic for MDMA-assisted therapy at Matilda Healthcare's Nepean Private Hospital in New South Wales (NSW) (BD: Apr 29, 2026).

Emyria executive chair Greg Hutchinson said the company was “delighted with the progress being made towards the opening of our first Sydney clinic”.

“With the fit-out complete, our initial clinical team trained, authorized prescribers in place and key medication and healthcare partnerships secured, the operational foundations required for launch are now substantially established,” Mr Hutchinson said.

Emyria was up 0.2 cents or 4.35 percent to 4.8 cents with 2.4 million shares traded.

CLINUVEL PHARMACEUTICALS

Clinuvel says it has completed the development of Zerokin for single-use subcutaneous drug delivery.

Clinuvel said that Zerokin would be used to administer controlled-release formulations developed by its Singapore research, development and innovation centre.

The company said that Zerokin was intended as a class II device, which would require registration for human use with the US Food and Drug Administration via the 510(k) pathway, and an application for Conformité Européenne (CE) mark under the EU Medical Device Regulations.

Clinuvel chief scientific officer Dr Dennis Wright said that the company's scientific teams had "taken extensive feedback on the use of our drug Scenasse and other peptides in the clinic to try ... [to] anticipate how these products could better serve patient and physician needs".

"The bespoke Zerokin device is the direct result of this process, which we will now fast track to finished manufacture and regulatory filing," Dr Wright said.

"It is an important step forward alongside our formulation work in Singapore," Dr Wright said.

Clinuvel fell nine cents or 1.1 percent to \$8.07 with 132,154 shares traded.

ANTEOTECH

Anteotech says it has a supply agreement for battery design and prototyping with Adelaide's Airspeeder Pty Ltd which is involved in electric flying car design and racing.

Anteotech fell 0.3 cents or 12.5 percent to 2.1 cents with 6.7 million shares traded.

BLINKLAB

Blinklab says Apple Health's former clinical lead for mental health Dr Raphael Bernier will replace Dr Richard Hopkins as a non-executive director, effective immediately.

Blinklab said that Dr Bernier had experience translating clinical science into digital products, including leading clinical development of Apple's Mental Wellbeing application for iPhone, iPad and Apple Watch.

The company said that Dr Bernier was the former executive director of the Seattle Children's Autism Center, one of the largest autism clinical programs in the US and a chair in child psychiatry at the University of Washington, having authored more than 200 scientific articles and two books, as well as serving as principal or co-investigator on more than 40 studies on the causes and neuroscience of autism and related neuro-developmental disorders.

Blinklab said the appointment of Dr Bernier strengthened the board as the company targets US Food and Drug Administration 510(k) submission by April 2027.

The company said that Dr Bernier held degrees from the University of Wisconsin and Tufts University, and held a Doctor of Philosophy from the University of Washington.

Blinklab said that Dr Richard Hopkins was appointed to the board in May 2022 and "contributed his experience in biotechnology leadership, corporate strategy, financing, business development and intellectual property during a period of significant growth".

The company expressed its "gratitude to Dr Hopkins for his service and counsel, including his contribution as Blinklab progressed from its ASX listing through the development and execution of its US clinical and regulatory strategy".

Blinklab was up 1.5 cents or 1.95 percent to 78.5 cents.

NEUROTECH INTERNATIONAL

Neurotech says it has appointed Andrew Chapman as a director, Dr Anthony Filippis has resigned as managing director and director Max Johnston will retire in November.

Neurotech said that Mr Chapman was the founder of Merchant Funds Management and had more than 25 years' experience in the financial services industry.

The company said that Mr Chapman was currently a Director of Argent and chair of Cycliq Group.

Neurotech said that Mr Chapman held a Bachelor of Commerce.

The company said that Dr Filippis had resigned and Robert Maxwell Johnston would retire as a director following the annual general meeting scheduled for November 5, 2026.

Neurotech said that executive chair Mark Davies will continue to provide "continuity of leadership".

The company said it thanked Dr Filippis and Mr Johnston "for their valuable contributions ... during their time in office and wishes them well in their future endeavors.

Last month, Perth's Merchant Funds Management said it became a substantial shareholder in Neurotech with 118,698,491 shares, or 7.38 percent (BD: Aug 13, 2026).

Neurotech was unchanged at 1.3 cents with 7.7 million shares traded.